News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates.
Breaking Arvinas VEPPANU (Vepdegestrant) Receives FDA Approval as First PROTAC Drug for ESR1-Mutated Breast Cancer
Arvinas' VEPPANU becomes the first FDA-approved PROTAC drug for ESR1-mutated, ER+/HER2- advanced breast cancer, marking a breakthrough in protein degradation therapy.
3 min read Latest News
CRISPR Therapeutics' CASGEVY Reaches 60,000+ Eligible Patients Across 10 Countries Following Global Approvals
CRISPR Therapeutics reports CASGEVY now approved in 10 countries for severe sickle cell disease and beta thalassemia, reaching over 60,000 eligible patients worldwide.
Clene's CNM-Au8 Gets FDA Green Light for Accelerated Approval Pathway in ALS Treatment
FDA confirms Clene's CNM-Au8 ALS drug can proceed via accelerated approval pathway using neurofilament light biomarker data, with NDA filing expected Q3 2026.
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen in McCune-Albright Syndrome
Atossa Therapeutics gains FDA Rare Pediatric Disease designation for (Z)-endoxifen treating McCune-Albright syndrome, qualifying for Priority Review Voucher.
mBIOTA Elemental Diet Shows Promise for IBS Treatment in New Clinical Trial Data Presented at DDW 2026
New clinical trial data validates mBIOTA Elemental as effective IBS therapeutic, showing symptom improvement across all three IBS subtypes at DDW 2026.
Novartis Receives Health Canada Approval for Fabhalta Oral Treatment for C3G Patients
Health Canada approves Novartis' Fabhalta (iptacopan) oral treatment for adults with complement 3 glomerulopathy, offering new hope for rare kidney disease patients.
ASCO 2026: Cellectar's Waldenström Macroglobulinemia Data
Cellectar Biosciences will present CLOVER WaM (iopofosine I 131) data at ASCO 2026, focusing on efficacy subset data in relapsed/refractory Waldenström macroglobulinemia.
Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Pancreatic Cancer Trials at DDW 2026
Alpha Tau reports 100% local disease control with Alpha DaRT device in heavily pre-treated pancreatic cancer patients with favorable safety profile.
Cytokinetics to Report Aficamten Phase 3 Trial Results for Non-Obstructive Hypertrophic Cardiomyopathy May 5, 2026
Cytokinetics announces topline results from pivotal ACACIA-HCM Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy on May 5, 2026.
InflaRx Izicopan Shows Low Reactive Metabolite Formation in Liver Safety Study
InflaRx reports favorable safety data for Izicopan showing low reactive metabolite formation in human liver microsomes, reducing bioactivation risks.
MacroGenics Expands ZYNYZ Royalty Agreement with Sagard Healthcare Partners for Cancer Drug
MacroGenics expands its ZYNYZ royalty purchase agreement with Sagard Healthcare Partners, providing additional funding for the cancer immunotherapy drug.
Akebia Therapeutics Vadadustat Shows Significant Mortality Reduction in New Kidney Disease Analysis
Akebia Therapeutics announces Vadadustat post-hoc analysis published in JASN shows statistically significant reduction in mortality and hospitalization for kidney disease patients.
InflaRx Reports Favorable Safety Profile for Izicopan in Liver Metabolism Study
InflaRx announces positive pre-clinical data showing low reactive metabolite formation for izicopan in human liver microsomes, supporting drug safety profile.
Celcuity's Gedatolisib Meets Phase 3 Primary Endpoint in PIK3CA Mutant Cancer Trial
Celcuity's VIKTORIA-1 Phase 3 trial shows clinically meaningful progression-free survival improvement with gedatolisib in PIK3CA mutant patients.
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market
FDA approves LANGLARA as interchangeable biosimilar to Lantus insulin glargine, marking Lannett Company's entry into diabetes treatment market through Lanexa Biologics.
FDA Approves Guardant360 CDx as Companion Diagnostic for Pfizer's VEPPANU in ER+/HER2- Breast Cancer
Guardant Health receives FDA approval for blood-based companion diagnostic to identify patients eligible for VEPPANU treatment in advanced breast cancer with ESR1 mutations.
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis and Blood Disorders
Incyte receives FDA approval for once-daily Jakafi XR (ruxolitinib) extended-release tablets for myelofibrosis, polycythemia vera, and GVHD treatment.
Excipient World Conference: Key Highlights and Industry Trends
The Excipient World Conference 2026 highlighted major advances in pharma excipients, including innovations in drug delivery, regulatory compliance strategies, and sustainable formulation technologies shaping the future of pharmaceutical development.
APHL 2026 Annual Meeting: Day 1 Highlights
Day 1 of the APHL 2026 Annual Meeting featured discussions on innovative diagnostic approaches and collaborative strategies in public health laboratory science.
APHL 2026: Day 1 Highlights and Key Takeaways
Day 1 of APHL 2026 focused on innovations in public health laboratory practices and emerging technologies. The opening keynote addressed the importance of data-driven decision-making in public health.